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Abstract
In spite of widespread anecdotal and scientific evidence much remains to be understood about the long-suspected
connection between psychological factors and susceptibility to cancer. The skin is the most common site of cancer,
accounting for nearly half of all cancers in the US, with approximately 2–3 million cases of non-melanoma cancers occurring
each year worldwide. We hypothesized that a high-anxious, stress-prone behavioral phenotype would result in a higher
chronic stress burden, lower protective-immunity, and increased progression of the immuno-responsive skin cancer,
squamous cell carcinoma. SKH1 mice were phenotyped as high- or low-anxious at baseline, and subsequently exposed to
ultraviolet-B light (1 minimal erythemal dose (MED), 3 times/week, 10-weeks). The significant strengths of this cancer model
are that it uses a normal, immunocompetent, outbred strain, without surgery/injection of exogenous tumor cells/cell lines,
and produces lesions that resemble human tumors. Tumors were counted weekly (primary outcome), and tissues collected
during early and late phases of tumor development. Chemokine/cytokine gene-expression was quantified by PCR, tumor-
infiltrating helper (Th), cytolytic (CTL), and regulatory (Treg) T cells by immunohistochemistry, lymph node T and B cells by
flow cytometry, adrenal and plasma corticosterone and tissue vascular-endothelial-growth-factor (VEGF) by ELISA. High-
anxious mice showed a higher tumor burden during all phases of tumor development. They also showed: higher
corticosterone levels (indicating greater chronic stress burden), increased CCL22 expression and Treg infiltration (increased
tumor-recruited immuno-suppression), lower CTACK/CCL27, IL-12, and IFN-c gene-expression and lower numbers of tumor
infiltrating Th and CTLs (suppressed protective immunity), and higher VEGF concentrations (increased tumor angiogenesis/
invasion/metastasis). These results suggest that the deleterious effects of high trait anxiety could be: exacerbated by life-
stressors, accentuated by the stress of cancer diagnosis/treatment, and mediate increased tumor progression and/or
metastasis. Therefore, it may be beneficial to investigate the use of chemotherapy-compatible anxiolytic treatments
immediately following cancer diagnosis, and during cancer treatment/survivorship.
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Introduction
Numerous studies have suggested that stress-prone personalities
and coping styles, and factors like trait anxiety that contribute to
increased stress, are associated with higher cancer incidence,
progression or mortality [1–8]. However, many studies have failed
to find an association between stress-related personality traits and
cancer incidence and/or mortality [9–13]. Differences in the
timing of personality assessment relative to cancer diagnosis,
interactions between personality type, stressor severity, and related
factors [14,15], methodological heterogeneity among studies [16],
and a focus on immunoresistant tumors in some studies [17], are
thought to explain the equivocal nature of findings concerning
personality factors and susceptibility to cancer. Importantly,
cancer patients across diverse cultures consistently rank stress as
a major contributing factor to their disease [18–21] and numerous
studies have shown that long-term stress is related to increases in
tumor incidence, progression, and metastasis [22–29] (for review
see: [30]). In light of this background we investigated the
association between anxiety-related behavioral phenotypes and
cancer susceptibility under controlled laboratory conditions and in
the context of an immuno-responsive cancer. Previous studies
using the same tumor model described here, had shown that
chronic stress increases susceptibility to squamous cell carcinoma
(SCC) by suppressing protective immunity and increasing
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[25]. Anxiety may be defined as increased sensitivity and/or
reactivity to actual and physically existent, or non-existent but
perceived or anticipated threats/stressors. Because it is likely that
a high-anxious behavioral phenotype can induce greater stress-
reactivity and lead to an increased chronic stress load over time,
we tested the overall hypothesis that anxiety-related behavioral phenotypes
measured at baseline (pre-cancer) would be associated with physiological
indices of increased chronic stress, decreased protective immunity, and increased
susceptibility to UV-induced SCC.
The SCC model described here has several advantages: it
involves a normal, immuno-competent, outbred mouse strain
that has not been genetically manipulated, does not involve
surgery or injection of exogenous tumor cells or cell lines, and
allows investigation of the naturalistic time course of all phases of
tumor development [25] with lesions and stages that closely
resemble human SCC [31–33]. Importantly, the public health
relevance of these studies is highlighted by the fact that the skin
is the most common site of cancer in humans [34], with an
estimated 2–3 million cases of non-melanoma skin cancers
occurring each year worldwide [35]. SCC is the second most
common type of cancer in the United States, with approximately
700,000 cases being diagnosed and resulting in approximately
2,500 deaths each year [36]. Furthermore, the ultraviolet B
(UVB) component of sunlight (same wavelengths, 290–320 nm,
used to induce SCC in the present model) is a complete
carcinogen and is responsible for most non-melanoma skin
cancers [37,38]. Importantly, SCCs are immunogenic and can be
eliminated by endogenous cell-mediated immune responses [39–
41], however, UV exposure suppresses lymphocyte trafficking,
and T and NK cell function [42], and inhibits anti-SCC
immunity [43–45], all of which may enable SCC tumors to
escape immune clearance [25,46]. In light of the importance of
anxiety being generated during the diagnosis and treatment of
cancer, and the global health relevance and scientific value of the
skin cancer model under study, here we investigate endocrine
(physiological indices of chronic stress burden), immune (indices
of protective versus suppressive immune function in the tumor
microenvironment), and tumor growth-promoting (VEGF) me-
chanisms mediating the effects of high- versus low-anxious
behavioral phenotypes on tumor emergence and progression.
Results
Classification of Mice into High- versus Low-anxious
Phenotypes at Baseline
We used two established ethological tests of anxiety-related
behavior, the elevated plus maze (EPM) and the light-dark arena
(LDA), to determine the anxiety-related behavioral phenotype of
each mouse [47–49] at baseline, i.e., before tumor induction.
Two different tests were used because anxiety is a complex
behavioral phenotype and we wanted to examine whether
different dimensions of anxiety (that are likely to be evoked
and quantified in different testing arenas) would be associated
with specific aspects of tumor progression and/or tumor-relevant
immune function. In addition, the open field arena (OFA) was
used to determine the overall level of activity/locomotion as
a control measure, to ensure that relationships observed using the
EPM or LDA anxiety measures were not the result of inter-
individual differences in overall activity levels [48,50]. Mice were
classified as high- or low- anxious on the basis of a median-split
of the scores for each test. The resulting medians and group
means are shown in Table 1. The difference between mice
showing the high- versus low- anxious behavioral phenotype on
each test was highly significant (p ,= 0.0001) only when the
above- versus below- median groups were compared for the test
on which the median split was based, indicating independence
among the behavioral measures.
High-anxious Mice Show Increased Tumor Emergence
and Progression
Mice that showed a high-anxious phenotype at baseline (as
measured by the EPM) exhibited a greater tumor burden during
all phases of tumor development (Fig. 1): papilloma emergence
and regression (,weeks 11–19), transition from papilloma to SCC
(,weeks 20–25), and SCC progression (,week 26 onwards).
Interestingly, no statistically significant differences in mean tumor
counts were observed when mice were grouped into high- versus
low- anxious phenotypes on the basis of their behavior in the LDA.
Using total distance traveled in the OFA as a control measure for
differences in overall activity levels between individual mice, we
found no differences in tumor counts between high- versus low-
locomotor activity phenotypes (p . 0.1). This suggested that the
observed relationship between high-anxious phenotype and
increased tumor burden is not the result of differences in overall
locomotor activity but is related to anxiety. No statistically
significant differences were observed in average tumor area, or
time to 50% tumor incidence, when mice were grouped by high-
versus low- anxious phenotypes, or by high- versus low- locomotor
activity (p . 0.1). This suggested that while the high-anxious
behavioral phenotype was associated with a higher count of
tumors, no association was detected with tumor size or time to
50% tumor incidence.
The quantitative assessment of tumors described above was
complimented with histopathological examination and identifica-
tion of tissue characteristics of tumors at week 31. From the mice
that were euthanized at week 31 we submitted one tumor from
every animal that had a tumor with a diameter . 3 mm for
histopathological classification. A total of eighteen tumors were
classified. In mice characterized as high-anxious (HiAnx) in the
EPM, one apparent tumor was reclassified as focal epidermal
Table 1. Classification of mice into low- versus high- anxious (EPM & LDA) or active (OFA) groups at baseline.
Behavioral Test Measure MEDIAN
MEAN (SEM)
Below-Median
Group
MEAN (SEM) Above-
Median Group t-test (p)
Elevated Plus Maze (EPM) Time spent in closed arms (sec) 133 115 (3) 148 (2) *
Light Dark Arena (LDA) Time spent in dark (sec) 120 44 (8) 157 (4) *
Open Field Arena (OFA) Total distance travelled (cm) 456 311 (20) 683 (47) *
*p ,= 0.0001, t-test.
doi:10.1371/journal.pone.0033069.t001
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tumors, four were papillomas, two were microinvasive SCC
(miSCC), and two were fully invasive SCC. In mice characterized
as low-anxious (LoAnx) in the EPM, five tumors were classified as
papilloma, four as miSCC, and none as SCC. Mice characterized
as HiAnx in the LDA had four papillomas, four miSCC, and two
SCC. Among tumors sampled in mice characterized as LoAnx in
the LDA, one was reclassified as focal epidermal hyperplasia, five
were papillomas, two were miSCC, and none were SCC.
Therefore, only mice characterized as HiAnx in either the EPM
or the LDA had fully invasive SCC. Moreover, both groups of
HiANx mice had a higher proportion of invasive miSCC or SCC
compared to non-invasive papillomas ($50% of tumors). Quali-
tatively, these findings suggest accelerated tumor progression in
high-anxious individuals.
Effects of High- versus Low-anxious Phenotypes on
Chemokine and Cytokine Gene Expression in UV Exposed
Skin and UV-induced Tumors
We examined the effects of high- versus low-anxious
behavioral phenotypes on mean levels of gene expression of
critical chemokines and cytokines that are known to have
important protective (cutaneous T cell attracting chemokine
(CTACK also known as CCL27), interleukin (IL)-12, interferon
gamma (IFN-c)) versus tumor-promoting (CCL22, IL-10, IL-4)
effects in the context of SCC [25,51]. Since overall biological
function is ultimately influenced by relative proportions of
counteracting factors, we also examined the effects of anxiety
phenotype on the ratios of protective versus harmful chemokines
(CTACK/CCL22) and cytokines ((IL-12+IFN-c)/(IL-10 + IL-4)).
To assess robustness of findings, effect size calculations (Cohen’s
d), and multivariate regression analyses were performed in
addition to t-tests. Therefore, t-test p values with effect size
calculated as Cohen’s d, and/or regression p values with
regression slope, are provided below for all analyses showing
statistical significance (p , 0.05) or trend (p , 0.09). Importantly,
for all comparisons where one of the two analyses, t-test or
regression slope, showed a statistical trend, the remaining analysis
showed statistical significance, the only exceptions being gene
expression in UV exposed skin at week 17 for IFN-c and at week
31 for the ratios of CTACK/CCL22 and (IL-12+IFN-c)/(IL-
4+IL-10), for which the t-test was not significant and the
regression slopes only showed statistical trends.
Gene expression was quantified in UV-exposed skin without
visible lesions at weeks 17 and 31 in order to examine pre-
cancerous changes (Fig. 2): At week 17, HiAnx mice showed lower
levels of gene expression for CTACK (regression slope = –0.5,
p , 0.05), IL-12 (t-test p , 0.05, effect size = 0.9; regression slope
= –0.5, p , 0.09) and IFN-c (t-test p , 0.09, effect size = 0.7) and
higher gene expression for IL-4 (t-test p , 0.05, effect size = 0.8;
regression slope = 0.5, p , 0.05) while CCL22 and IL-10 gene
expression levels were not detectably different between the two
groups (Fig. 2). At week 31, UV exposed skin of HiAnx mice
showed lower levels of gene expression for CTACK (t-test p ,
0.05, effect size = 0.6; regression slope = –0.4, p , 0.01), IL-12
(regression slope = –0.4, p , 0.05) and IFN-c (t-test p , 0.05,
effect size = 0.7; regression slope = –0.5, p , 0.01). CCL22, IL-
4, and IL-10 gene expression at week 31 was not detectably
different between HiAnx and LoAnx mice, however, HiAnx mice
showed a lower ratio of CTACK/CCL22 (regression slope = –
0.2 p , 0.09), and of protective (IL-12 + IFN-c) to harmful (IL-10
+ IL-4) cytokines (regression slope = –0.5, p , 0.09).
Gene expression was quantified in tumors at week 31 (Fig. 3):
Tumors from HiAnx mice showed a higher levels of CCL22 gene
expression (t-test p , 0.09, effect size = 0.5; regression slope =
0.4, p , 0.05), a lower ratio of CTACK/CCL22 (t-test p , 0.05,
effect size = 0.6; regression slope = –0.3 p , 0.05), and a lower
ratio of protective (IL-12 + IFN-c) to harmful (IL-10 + IL-4)
cytokines (t-test p , 0.09, effect size = 0.8; regression slope = –
0.5, p , 0.05). The differences in gene expression between HiAnx
and LoAnx mice described in this section were based on anxiety
phenotype determined by the LDA, except for differences in IL-4
gene expression which were based on anxiety phenotype de-
termined by the EPM.
Tumors of High-anxious Mice Show Lower Numbers of
Protective T cells and Higher Numbers of Regulatory/
Suppressor T Cells
We quantified the numbers of critical tumor infiltrating
lymphocyte populations that are known to have important
protective (helper and cytolytic T cells) or harmful (regulatory
T cells) effects in the context of SCC in LoAnx and HiAnx mice
(Fig. 4). Representative photomicrographs are also shown (Fig. 5).
HiAnx mice as phenotyped on the basis of behavior in the LDA
showed lower numbers of tumor infiltrating Th cells (t-test p ,
0.07, effect size = 0.6; regression slope = –0.5, p , 0.05) and
CTLs (t-test p , 0.05, effect size = 0.8), higher numbers of Tregs
(regression slope = 0.37, p , 0.09) and lower ratios of Th/Treg
(t-test p , 0.05, effect size = 1.0; regression slope = –0.5, p ,
0.05), CTL/Treg (t-test p , 0.05, effect size = 0.7; regression
slope = –0.4, p , 0.09), and (Th+CTL)/Treg (t-test p , 0.05,
effect size = 1.1; regression slope = –0.6, p , 0.05). This suggests
that the balance between immuno-protective versus immuno-
regulatory/suppressive cells was shifted in favor of active Treg-
mediated suppression of anti-tumor immunity in HiAnx mice.
Figure 1. Effects of anxiety phenotype on tumor emergence
and progression. Compared to low-anxious mice (white bars) high-
anxious mice (black bars) showed a higher mean tumor count during all
phases of tumor development: papilloma emergence and regression
(,weeks 11–19), transition to SCC (,weeks 20–25), and SCC pro-
gression (,week 26 onwards). Data are expressed as mean 6 SEM.
Statistically significant differences between phases are indicated (** p ,
0.05; *** p , 0.01). Analysis employed a generalized linear model for
a Poisson distribution on a logarithmic link function with allowance for
overdispersion of the area data.
doi:10.1371/journal.pone.0033069.g001
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was measured by quantitative PCR at weeks 17 and 31 in low- (white bars) and high- (black bars) anxiety mice. mRNA levels of chemokines and
cytokines known to be protective (CTACK, IL-12, and IFN-c) or harmful (IL-4 and IL-10) in the context of SCC were quantified. Levels of mRNA
expression normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA are shown. Data are expressed as mean 6 SEM. Outcomes
were optimally Box-Cox transformed prior to analysis. For each outcome, means were compared between groups using a two-sample t-test with
Satterthwaite adjustment for unequal variances. Statistical trends (* p , 0.09) and significant differences (** p , 0.05) are indicated, and
corresponding effect sizes are mentioned in the text. For all comparisons where the t-test showed a statistical trend, regression analysis showed
statistical significance, the only exception being week 17 IFN-c gene expression.
doi:10.1371/journal.pone.0033069.g002
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e33069Figure 3. Effects of anxiety phenotype on chemokine and cytokine gene expression in tumors. Gene expression in tumors was measured
by quantitative PCR at week 31 in low- (white bars) and high- (black bars) anxiety mice. mRNA levels of chemokines and cytokines known to be
protective (CTACK, IL-12, and IFN-c) or harmful (IL-4 and IL-10) in the context of SCC were quantified. Since overall biological function is ultimately
influenced by relative proportions of counteracting factors, we also examined the effects of anxiety phenotype on the ratios of protective versus
harmful factors: CTACK/CCL22 and (IL-12+IFN-c)/(IL-10 + IL-4). Levels of mRNA expression normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA are shown. Data are expressed as mean 6 SEM. Statistical trends (* p , 0.09) and significant differences (** p , 0.05) are indicated.
Outcomes were optimally Box-Cox transformed prior to analysis. For each outcome, means were compared between groups using a two-sample t-
test with Satterthwaite adjustment for unequal variances.
doi:10.1371/journal.pone.0033069.g003
Figure 4. Effects of anxiety phenotype on tumor infiltrating helper (Th), cytolytic (CTL), and regulatory (Treg) T cells. Tumor
infiltrating T cells were quantified in low- (white bars) and high- (black bars) anxiety mice at week 31. Numbers of tumor infiltrating cells that are
known to be protective (Th and CTL) or harmful (Treg) in the context of SCC were quantified. Since overall biological function is ultimately influenced
by relative proportions of counteracting cells, we also examined the effects of anxiety phenotype on the ratios of protective versus harmful factors:
Th/Treg, CTL/Treg, and (Th + CTL)/Treg. The number of positive cells per standardized field was counted by a blinded observer. Five fields at 60x were
analyzed per stained tumor section per mouse. Data are expressed as mean 6 SEM. Statistical trends (* p , 0.09) and significant differences (** p ,
0.05) are indicated. Outcomes were optimally Box-Cox transformed prior to analysis. For each outcome, means were compared between groups
using a two-sample t-test with Satterthwaite adjustment for unequal variances.
doi:10.1371/journal.pone.0033069.g004
High Anxiety and Increased Cancer Susceptibility
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e33069Sentinel Lymph Nodes of High-anxious Mice Show
a Lower Proportion of CD4+ Helper T Cells and a Higher
Proportion of B Cells
The relative percentages of Th (CD3+CD4+), CTL
(CD3+CD8+) and B (B220+) cells in left and right brachial lymph
nodes (2 lymph nodes per mouse) collected at week 31 are shown
in Table 1. Brachial lymph nodes were examined because they are
representative of sentinel lymph nodes that drain the dorsum,
where a majority of the tumors were observed. Lymph nodes of
high-anxious mice, phenotyped on the basis of their behavior in
the LDA, showed a lower percentage of Th cells (t-test p , 0.05,
effect size = 0.7; regression slope = –0.5, p , 0.01) and higher
percentage of B cells (t-test p , 0.01, effect size = 0.8; regression
slope = 0.6, p , 0.01) compared to those of low-anxious mice. No
detectable differences in percentages of CTLs were observed.
High-anxious Mice Express Higher Levels of Total Adrenal
and Peak Stress Corticosterone
We investigated the relationship between high- versus low-
anxious phenotype and stress-reactivity of the hypothalamic-
pituitary-adrenal (HPA) axis, measured by plasma corticosterone
secretion, as a possible mechanism mediating the effects of anxiety
phenotype on immune function and susceptibility to cancer.
HiAnx mice, phenotyped on the basis of their behavior in the
EPM (but not the LDA), showed higher total adrenal corticoste-
rone levels than LoAnx mice (HiAnx = 98.7 6 11.5 mg, LoAnx
= 73.9 6 9.4 mg, t-test p , 0.05, effect size = 0.6; regression
slope = 0.3, p , 0.09). Resting state plasma corticosterone levels
were not significantly different between HiAnx and LoAnx mice.
However, when exposed to an acute stressor (0.5 h restraint),
HiAnx mice, phenotyped on the basis of their behavior in the
LDA (but not the EPM), also showed higher peak stress
corticosterone levels compared to LoAnx mice (high-anxious =
62.3 6 6.3 mg/dL, low-anxious = 47.6 6 8.2 mg/dL, t-test p ,
0.05, effect size = 0.7). Taken together, these data indicate that
HiAnx mice may be chronically exposed to higher levels of
corticosterone, with higher peak stress corticosterone suggesting
that high-anxious mice were likely to mount a greater stress
response to moderate stressors such as cage changes or social
interactions and with higher total adrenal corticosterone levels
providing further evidence of a long-term or chronic increase in
HPA axis activity.
Figure 5. Photomicrographs showing the effects of anxiety phenotype on tumor infiltrating helper (Th), cytolytic (CTL), and
regulatory (Treg) T cells. Immunohistochemical staining for CD4 (top row), CD8 (middle row), and CD25 (bottom row) was used to enumerate
(counts shown in Fig. 4) tumor infiltrating T cells from low- (left column) and high- (right column) anxious mice at week 31. Scale bar denotes 100 mm.
doi:10.1371/journal.pone.0033069.g005
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Endothelial Growth Factor (VEGF)
Tissue VEGF has been used as a prognostic indicator for SCC
[52,53]. We investigated the relationship between high- versus
low-anxious phenotype and VEGF concentrations within the
tissue microenvironment of HiAnx versus LoAnx mice. HiAnx
mice, phenotyped on the basis of their behavior in the LDA (but
not the EPM), showed higher VEGF concentrations in skin lesions
(diameter , 2 mm) that represent a transition from focal
epidermal hyperplasia to true papilloma and are part of the
spectrum of lesions leading ultimately to SCC [54,55] (HiAnx =
76.0 6 16.7 pg/ml, LoAnx = 45.1 6 10.1 pg/ml, t-test p , 0.09,
effect size = 0.6). HiAnx mice also showed higher VEGF
concentrations in UV-exposed skin where there were no visible
lesions (HiAnx =29.9 6 5.5 pg/ml, LoAnx = 20.0 6 2.7 pg/ml,
t-test p , 0.09, effect size = 0.6; regression slope = 0.5, p , 0.05).
Discussion
Numerous studies have shown that stress-prone personality and
coping styles and factors like trait anxiety are associated with
higher cancer incidence and/or increased mortality [1–8],
however, other studies have failed to find associations between
personality traits and cancer incidence and/or mortality [9–13].
Insightful reviews suggest that the equivocal nature of findings
concerning personality factors and susceptibility to cancer are due
to the timing of personality assessments relative to cancer
diagnoses; interactions among personality type, stressor severity,
and related factors [14,15]; methodological heterogeneity among
studies [16]; and a focus on immuno-resistant tumors in some
studies [17]. The study described here investigated the association
between baseline (pre-cancer) anxiety phenotype and cancer
susceptibility under controlled laboratory conditions and in the
context of an immuno-responsive tumor.
Anxiety Phenotype and Tumor Burden
We tested the hypothesis that mice exhibiting a high-anxious
behavioral phenotype at baseline would be more susceptible to
UV-induced SCC compared to mice exhibiting a low-anxious
phenotype. Supporting this hypothesis, we found that HiAnx mice
exhibited a greater tumor burden during all phases of tumor
development (Fig. 1): papilloma emergence and regression
(,weeks 11–19), transition from papilloma to SCC (,weeks 20–
25), and SCC progression (,week 26 onwards). We found no
further association between anxiety phenotype and time to tumor
onset. This shows that a high-anxious phenotype does not hasten
tumor incidence but is associated with increased tumor count and
progression once tumors begin to emerge. These findings suggest
that it may be beneficial, especially for high-anxious patients, to
receive behavioral and/or chemotherapy-compatible pharmaco-
logical anxiolytic treatment soon after cancer diagnosis and during
and following cancer treatment. These findings are in agreement
with elegant studies in rats showing that a high-anxious, neophillic
phenotype [56], or the anxiogenic and stress-inducing effects of
social isolation [57], may contribute to increased susceptibility to
mammary tumors.
Chemokine and Cytokine Mediators
In order to identify immunological mechanisms that may
mediate differences in tumor susceptibility between HiAnx and
LoAnx mice, we examined gene expression of critical chemokines
and cytokines known to exert protective versus harmful effects in
the context of SCC. Factors likely to increase protective immunity
against SCC were CTACK (also known as CCL27), a chemokine
that is crucial for recruiting skin-homing T cells to sites of
cutaneous immune activation [58–60], and IL-12 and IFN-c,
cytokines that are critical for the initiation and maintenance of
cell-mediated [61,62] and anti-tumor immunity [63–67]. Factors
that are known to promote SCC progression and have been
associated with poor prognosis included CCL22, a chemokine that
attracts regulatory T cells (Tregs) that shut down the anti-tumor
immune response [68–71], IL-10, an immuno-regulatory/sup-
pressive cytokine [72–75], and IL-4, a prototypical Th2 cytokine
[76–79]. Gene expression was quantified in skin that was devoid of
detectable lesions in order to examine early changes in cutaneous
immunity in the absence of tumors (Figure 2), as well as in tumors
(Figure 3). Results showed that UV-exposed skin as well as tumors
of HiAnx mice expressed lower levels of protective chemokines
and cytokines than LoAnx mice. Since the biological actions of
chemokines and cytokines often involve changes in the balance
between counteracting factors, we also examined the effects of
high- versus low-anxious phenotype on the ratio of protective to
harmful factors. Tumors from HiAnx mice showed lower ratios of
CTACK/CCL22 and (IL-12+IFN-c)/(IL-10+IL-4). Taken together,
these data suggest that the chemokine balance in tumors of HiAnx mice is
shifted towards CCL22, which attracts regulatory/suppressor T cells that
suppress anti-tumor immunity, and away from CTACK, which may attract
protective anti-tumor T cells. Correspondingly, the cytokine balance in HiAnx
mice is shifted towards immuno-regulatory/suppressive (IL-10) and type-2
(IL-4) cytokines and away from Type-1 cytokines like IL-12 and IFN-c that
are known to protect against SCC.
Immune Cell Mediators
Given the differences in chemokine and cytokine gene
expression described in the previous section, we quantified the
effects of high- versus low-anxious phenotype on sizes of critical
tumor infiltrating lymphocyte populations that are known to have
important protective or harmful effects in the context of SCC
(Fig. 4). Representative photomicrographs are also shown (Fig. 5).
Cell types known to mount anti-tumor immune responses against
SCC included CD4+ helper T cells (Th) and CD8+ cytolytic
T cells (CTL) [40,80–85]. The cell type known to favor tumor
progression by suppressing anti-tumor immunity, was the CD25+
regulatory/suppressor T cell (Treg) [68-71,86,87]. Since the
biological actions of these immune cell subpopulations often
involve changes in the balance between competing cell types, we
also examined the effects of high- versus low-anxious phenotype
on the ratios of protective to harmful cells: Results showed lower
numbers of infiltrating Th cells, higher numbers of Tregs, and
lower ratios of CD4/CD25, CD8/CD25 and (CD4+CD8)/
CD25 in tumors of HiAnx mice. This suggests that the balance
between immuno-protective versus immuno-regulatory/suppressive cells is
shifted in favor of active suppression of protective anti-tumor immunity by
Tregs in HiAnx mice.
We also examined the distribution of immune cell subpopula-
tions in brachial lymph nodes, the sentinel nodes that drain the
dorsum where most tumors are observed. HiAnx mice showed
a lower percentage and absolute number of Th cells and a higher
percentage and absolute number of B cells. This shift in
proportions of lymph node lymphocytes may be the result of
the Type-1 to Type-2 cytokine shift observed in HiAnx mice.
The increased tumor susceptibility of HiAnx mice may further
result from the lower proportion of Th cells and a decrease in
protective immunity in their sentinel lymph nodes. Importantly,
the increase in lymph node B cell percentages and numbers in
HiAnx mice may reflect an expansion of IL-10 secreting
regulatory B cells (B regs) [88,89]. While regulatory B cells need
to be further investigated in the context of anxiety, UV exposure
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regulatory B cells in sentinel lymph nodes [90] and inhibiting
anti-tumor T cell responses in SCC [91]. Taken together, these
findings suggest that in addition to increased regulatory T cells,
increased regulatory B cell numbers and activity may also
contribute to the higher IL-10 levels and mediate the decreased
protective immunity and increased tumor burden observed in
HiAnx mice.
Differential Associations with High- versus Low-anxious
Phenotype Measured in Different Ethological Arenas
We deployed two ethological tests for assessing anxiety-related
behavior because anxiety is a complex behavioral phenotype and
we wanted to determine whether different dimensions of anxiety
(that are likely to be evoked and quantified in different testing
arenas) are associated with specific aspects of tumor progression
and/or tumor-related endocrine, angiogenic, or immune factors.
Results showed that a high-anxious behavioral phenotype
characterized in the EPM but not the LDA was associated with
higher tumor counts, higher IL-4 gene expression in UV exposed
skin, and higher total adrenal corticosterone concentrations.
Interestingly, a high-anxious phenotype characterized in the
LDA was associated with a shift from protective to harmful
immune function, higher peak stress corticosterone concentra-
tions, and higher tissue VEGF concentrations. While specific
mechanisms mediating these differential relationships between
different measures of anxiety and different biological parameters
need to be investigated further, it is important to note that
overall anxiety-related behaviors are thought to be the result of
a balance between an animal’s need to avoid danger versus its
motivation to explore novel environments to increase access to
food and mates and that each of these measures of anxiety may
tap into different dimensions of the complex behavioral
phenotype. For example, anxiety-related quantitative trait loci
(QTL) have been found on different mouse chromosomes [92]:
a chromosome 15 QTL acts on avoidance behavior, and
a chromosome 1 QTL acts on exploration [92]. The distinct
physical characteristics of the EPM (elevated open ‘‘danger’’
zone) versus the LDA (flat illuminated ‘‘danger’’ zone) are likely
to measure different dimensions of anxiety. These findings
suggest that further research is necessary to identify the biological
pathways and mechanisms that link specific dimensions of
anxiety to tumor progression and/or tumor-related endocrine,
angiogenic, or immune factors in order to provide targets for
anxiety-ameliorating/eliminating pharmacological and/or behav-
ioral interventions following cancer diagnosis and during cancer
treatment. Importantly, these results show that whether defined
on the basis of the EPM or the LDA, a high-anxious phenotype
was associated with higher corticosterone concentrations (in-
dicating increased chronic stress), suppressed protective immuni-
ty, higher VEGF (indicating greater tumor angiogenesis/
metastasis) and significantly greater tumor burden. While much
work remains to be done, the coherence of the overall pattern of
findings that confirmed the a priori hypothesized biological
changes and mechanisms: i.e., increased tumor burden, de-
creased chemokine, cytokine, and cellular indices of protective
immunity, increased Treg-mediated suppression/tolerization of
anti-tumor immunity, and increased corticosterone and VEGF
levels, in HiAnx compared to LoAnx mice, and agreement with
the literature regarding the effects of chronic stress on cancer
[25,26], also speaks to the usefulness and relevance of the
approach used here.
Role of Stress-reactivity, Chronic Stress, and Endocrine
Factors
It is important to elucidate the neuroendocrine mechanisms
mediating the effects of anxiety phenotype on immune function
and/or tumor burden. Therefore, we hypothesized that a HiAnx
behavioral phenotype results in greater stress-reactivity to daily
life stressors that leads to increased chronic stress load over time.
For example, for a given stressor (e.g., social altercations with
cage mates, husbandry, cage changes, etc.), a HiAnx individual is
likely to mount a larger physiological stress response compared to
a LoAnx individual. Chronic stress has been shown to
dysregulate physiological, endocrine, and immune function and
to have numerous deleterious consequences that are thought to
be mediated by chronic exposure to glucocorticoid and
catecholamine stress hormones [93–96]. Specifically with respect
to cancer, numerous studies have shown that long-term stress is
related to increases in tumor incidence, progression, and
metastasis [22–27,97–99] (for review see: [30]). Chronic stress
has also been shown to increase susceptibility to SCC by
suppressing protective immunity and increasing regulatory T
cells within the tumor microenvironment [25]. Since glucocor-
ticoid hormones are important mediators of the effects of chronic
stress [93,94,96,100] we investigated the relationship between
anxiety-related behavioral phenotype and resting-state total
adrenal corticosterone and stress-induced plasma corticosterone,
as mediators of the effects of anxiety phenotype on immune
function and susceptibility to cancer. HiAnx mice showed higher
total adrenal corticosterone and stress-induced peak corticoste-
rone levels which suggests that HiAnx mice are chronically
exposed to higher levels of corticosterone than LoAnx mice. The
catecholamines, norepinephrine and epinephrine, are the other
two members of the triad of principal stress hormones that
together with cortisol/corticosterone mediate the effects of acute/
short-term and chronic/long-term stress. Although we were not
able to measure, and directly investigate the role of catechola-
mines, our results taken together with findings from other studies
[26,101-103], suggest that differences in systemic, tissue-associ-
ated, and/or tumor catecholamine levels are also likely to
mediate the effects of moderate chronic stress arising from a high-
anxious phenotype on suppressed immunity and increased
susceptibility to SCC.
Several mechanisms have been proposed through which stress
hormones can increase tumor burden. These include increased
production of vascular endothelial growth factor (VEGF) [104],
increased tumor metastasis [26,105], decreased tumor anoikis
[106] through activation of focal adhesion kinase [107], and
dysregulation or suppression of immune function (for review see:
[30,99]). The role played by these mechanisms in mediating the
effects of anxiety phenotype on tumor susceptibility merits further
investigation.
Role of VEGF
Tissue VEGF has been used as a prognostic indicator for
SCC [52,53] and VEGF has also been shown to be an
important mediator of chronic stress-induced enhancement of
tumor growth [26]. We did not have a sufficient number of
tumors for VEGF analysis because tumors were used for
histopathology, gene expression analysis and immunohistochem-
istry. However, we show here that HiAnx mice expressed higher
levels of VEGF protein in SCC precursor lesions and also in
UV-exposed areas of skin where no visible lesions were
observed. This suggests that increased VEGF production within
the tumor microenvironment of high-anxious mice may mediate
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Limitations and Future Directions
The limitations of this study are discussed and addressed as
follows: First, some of the observed differences between HiAnx
and LoAnx mice attained p values between 0.05 and 0.09 thus
indicating statistical trends. This is likely due to power limitations
that need to be addressed in future studies. However, to assess
robustness of findings, effect size calculations (Cohen’s d), and
multivariate regression analyses were performed in addition to t-
tests. The estimated medium to large effect sizes (Cohen’s d shown
for each comparison) speak to the possible statistical strength of the
observed effects. Furthermore, with few exceptions, for all
comparisons where one of the two analyses, t-test or regression
slope, showed a statistical trend, the remaining analysis showed
statistical significance. Importantly, the coherence of the overall
pattern of findings that confirmed the a priori hypothesized
biological changes and mechanisms: i.e., increased tumor burden,
decreased chemokine, cytokine, and cellular indices of protective
immunity, and increased corticosterone and VEGF levels, in
HiAnx compared to LoAnx mice, and agreement with the
literature regarding the effects of chronic stress on cancer
[25,26], suggests that the observed results were not random or
due to false positive findings. Second, sample size limitations were
likely to have been accentuated by the fact that these experiments
used an outbred strain that is expected to show greater gene and
gene-environment interaction driven variances than inbred strains.
However, a significant advantage of using an outbred strain is that
it provides a closer approximation of the genetic variation seen in
human populations. Third, while the present study focused on the
role of the HPA axis, the role of catecholamine hormones in
mediating the effects of high-anxious phenotypes on increased
tumor burden also needs to be examined. Fourth, while the
present study focused on the role of the immune system in
mediating the effects of anxiety phenotype on tumor susceptibility,
other potential mechanisms (e.g. tumor anoikis [106]) remain to be
investigated. Fifth, high-anxious mice are reported to exhibit
significantly higher levels of oxidative stress in the brain and
periphery [108] that suggests an oxidative stress related connection
between HiAnx phenotype and tumor progression that also
remains to be investigated. Sixth, the present study did not
deliberately expose the mice to chronic stress and therefore did not
examine the expected interaction between anxiety phenotype and
chronic stress. Future studies need to test the hypothesis that the
known deleterious effects of chronic stress on tumor incidence
and/or progression [25,26] will be exacerbated in HiAnx
individuals.
Clinical Implications
It is remarkable that an assessment of anxiety phenotype at
baseline, before tumor induction, predicted increased chronic
stress burden, lower protective immunity, increased tumor burden,
and increased angiogenic factors in the tumor microenvironment,
months later. While a high-anxious phenotype did not predict
early tumor incidence, it predicted increased tumor burden once
tumors began to emerge. In humans, trait anxiety has been
associated with increased chronic stress before [109] and after
[110,111] cancer diagnosis/treatment. Therefore, it may be
hypothesized that the effects of high trait anxiety may become
particularly relevant after cancer diagnosis, could be accentuated
by the stress of diagnosis and treatment, and may contribute to
increased tumor emergence, progression, and/or metastasis
through immune, stress-related endocrine, and other mechanisms.
Indeed, several lines of evidence highlight the clinical importance
of patient trait anxiety during cancer treatment and/or pro-
gression. High trait anxiety is associated with increased state
anxiety before chemotherapy [110] and increased conditioned
nausea and immuno-suppression during chemotherapy [111]. In
agreement with the data presented here, Lutgendorf et al. have
shown that higher levels of anxiety are associated with a Th1 to
Th2 shift in lymphocytes obtained from peripheral blood, tumors,
and ascites of ovarian cancer patients [112]. Pereira et al. have
shown a positive association between anxiety and higher anti-heat
shock protein 70 (HSP70) antibodies, indicating HSP70 over-
expression related to tumorigenesis in patients with endometrial
cancer [113]. Given that the SSC tumors studied here are known
to be susceptible to immune attack, and given that the high-
anxious phenotype is associated with lower anti-tumor immunity,
our findings also have implications for tumor immunotherapy
where the goal is to make immuno-resistant tumors responsive to
elimination by the immune system. Taken together, these findings
suggest that it may be beneficial to administer behavioral and/or
chemotherapy-compatible pharmacological anxiolytic treatments
to cancer patients (especially to high-anxious individuals) following
cancer diagnosis and during cancer treatment, and to cancer
survivors who report increased levels of anxiety. In addition to
reducing the psychological and physiological burden of chronic
stress, anxiolytic treatments are likely to conserve protective
immunity which is not only important for tumor elimination in
some cases, but also for overall immuno-protection against
environmental pathogens and insults and for healing wounded/
damaged tissues including those damaged by chemotherapy and
radiation.
Materials and Methods
Mice
All mice were maintained and monitored and experiments were
conducted according to protocol approved by the Institutional
Laboratory Animal Care and Use Committee of The Ohio State
University following guidelines established by the American
Association for Accreditation of Laboratory Animal Care
(AAALAC). Young adult (7–8 weeks) female SKH1 mice (Charles
River, Wilmington, Massachusetts) were housed (5 per cage,
except for two cages that had 4 mice each) in the AAALAC-
accredited animal facilities of The Ohio State University. SKH1
hairless mice are widely used in studies involving skin cancer, and
tumors closely resemble human SCC [31–33]. The animal room
was maintained on a 12-hour light-dark cycle (lights on at 6 am).
Mice were given food and water ad libitum.
Experimental Design
All mice were phenotyped for anxiety-related behaviors at
baseline following three weeks of acclimatization in the vivarium
after arrival from the supplier. One week after behavioral
phenotyping, all mice (n=48) were exposed to UVB three times
per week (,10 minutes/session) for ten weeks as previously
described [25,51]. Mice were monitored for tumor development
starting at week 11. Ten mice were euthanized (CO2 inhalation)
during week 17 to elucidate effects on early stages of tumor
formation and related measures of immune function. The rest of
the mice (n=38) were euthanized during week 31 to elucidate the
effects of anxiety phenotype on SCC progression and related
measures of immune factors, corticosterone and VEGF. Tissues
were immediately dissected, frozen, and stored at –70uC. Tumors
were either frozen for gene expression analysis, or fixed and
processed for histological analysis (described below).
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We used two ethological tests of anxiety-related behaviors,
elevated plus maze (EPM) and light-dark arena (LDA), to
determine the anxiety-related behavioral phenotype of each
mouse [47–49], and one test, open field arena (OFA), to determine
the level of activity/locomotion [48,50]. Mice were behaviorally
phenotyped after allowing them to acclimatize for 3 weeks
following arrival from the supplier. Behavioral testing was
performed one week before the beginning of UV exposure. All
animals were tested at the beginning of their active period. All
testing equipment and software was from Accuscan Instruments
(Columbus, Ohio). Anxiety Classification: The EPM and LDA
tests quantify anxiety-related behaviors by creating conditions that
tap into the intrinsic conflicts arising from the innate tendency of
mice to explore (in order to increase the probability of finding
food, water, and sex) and the innate fear/anxiety generated during
exploration of well-lit, exposed, or elevated areas, which increases
the probability of being attacked or killed by a predator or
conspecific aggressor. These arenas have been used to measure
trait anxiety in mice [114–116]. We used data from two
ethological tests (EPM and LDA) because each test is thought to
measure a different dimension of anxiety [92]. From the EPM we
used the time spent in the closed arms: compared to mice with
a low-anxious (LoAnx) phenotype, mice with a high-anxious
(HiAnx) phenotype would spend more time in the closed,
‘‘protected,’’ arms versus the open, ‘‘exposed,’’ arms of the
EPM. From the LDA we used time spent in the darkened area of
the arena: HiAnx mice would spend more time in the dark,
covered and ‘‘protected,’’ area of the arena, versus the lighted,
open and ‘‘exposed,’’ area of the arena. Mice were classified as
LoAnx versus HiAnx if respectively below versus above the
median of their EPM and LDA scores that were measured at
baseline. From the OFA we used total distance traveled as a control
measure of the overall locomotor activity of each mouse. This was
to ensure that any relationships observed using the EPM- or LDA-
based anxiety phenotypes were not merely the result of inter-
individual differences in overall activity levels. The resulting
medians and group means are shown in Table 1.
Tumor Counts and Measurements
None of the mice had SCC tumors at baseline. Mice were
monitored for tumor development (emergence, number, and size)
starting at week 11, when visible tumors first begin to appear. A
tumor was defined as a mass having a diameter of at least 1 mm.
Tumors were counted and measured weekly. The two longest
measurements (mm) in perpendicular directions were made using
a Cen-Tech digital caliper (Harbor Freight Tools, Camarillo,
California) and were multiplied to obtain a representation of
tumor area.
Stress Test
At week 30, all mice were subjected to a short-term/acute stress
test by placement in well-ventilated restrainers for 30 minutes.
This procedure mimics stress that is largely psychological in nature
because of the perception of confinement [117,118] and activates
the autonomic nervous system [119], the hypothalamic-pituitary-
adrenal axis [120,121], and adrenal steroid receptors in tissues
throughout the body [120,121]. Resting, and stress (30 min
restraint) plasma corticosterone concentrations were quantified
from ,50 ml of blood that was collected into heparinized tubes
from the retro-orbital sinus at each time point. Animals were
restored to their home cages after completion of the stress test.
Tumor Histology
Tumors were processed and histopathologic examination was
performed on the largest tumor (diameter . 3 mm) from each
animal as described previously [25,51]. Tumors were classified by
the team’s veterinary pathologist (DK).
Measurement of Gene Expression
Gene expression was measured in dorsal skin collected and
immediately frozen at weeks 17 and 31, and in tumors collected
and frozen at week 31. CTACK, IL-12p40, IFN-c, IL-4, IL-10,
and CCL22 gene expression was quantified using real-time
polymerase chain reaction (RT-PCR) as described previously
[25,51,122].
Preparation of Sentinel Lymph Node Cell Suspensions
Left and right brachial lymph nodes (2 per mouse) were placed
in ice-cold Hanks Balanced Salt Solution (HBSS) (Invitrogen,
Carlsbad, CA). A single cell suspension was prepared by squeezing
between frosted ends of microscope glass slides (Fisher Scientific,
Pittsburgh, PA), and filtering (70mm nylon) into HBSS. The cell
suspension was then washed twice and re-suspended in HBSS.
Cells were counted on a hematology analyzer (Beckman Coulter,
Miami, FL) and stained for flow cytometric analysis as described
below.
Tumor Leukocyte Quantification by
Immunohistochemistry
CD4+ and CD8+ and CD25+ T cells were quantified in tumors
at week 31. Tumor specimens were sectioned, processed, and
stained for CD4, CD8, and CD25 as described previously [25,51].
Positive cells per standardized field were counted by a blinded
observer. Five fields at 60x were analyzed per tumor section.
Lymph Node Leukocyte Quantification by Flow
Cytometry
Specific leukocyte subtypes were quantified in brachial lymph
node cell suspensions using multicolor flow cytometry (FACSCa-
libur, Becton Dickinson, San Jose, CA). Cells were incubated with
specific monoclonal antibodies for 25 min at room temperature,
washed with PBS, and analyzed on the FACSCalibur. Directly
conjugated rat anti-mouse CD3, CD4, CD8, and B220 (BD-
Pharmingen, San Diego, CA) antibodies were used to label cells.
Control samples matched for each fluorochrome and each
antibody isotype were used to set negative staining criteria.
Lymphocyte subtypes were identified as follows: helper T cells
(CD3+CD4+), cytolytic T cells (CD3+CD8+), and B cells (B220+).
Data were analyzed using CellQuest software (Becton Dickinson,
San Jose, CA).
Quantification of Plasma and Adrenal Corticosterone
Plasma corticosterone and total adrenal corticosterone were
measured by colorimetric ELISA according to manufacturer’s
instructions (Enzo Life Sciences, Ann Arbor, MI). Assay sensitivity
was 0.03 mg/dL, and intra- and inter-assay CVs were 4% and 9%
respectively.
Quantification of Tissue VEGF
VEGF concentrations were measured in UV-exposed skin that
had no visible lesions, as well as in skin lesions (diameter , 2 mm)
that represent a transition from focal epidermal hyperplasia to true
papilloma and are part of the spectrum of lesions leading
ultimately to SCC [54,55]. Each tissue was homogenized in lysis
buffer per manufacturer instructions, and VEGF levels were
quantified by a high-sensitivity sandwich immunoassay (Meso
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Statistical Analyses
Figure 1: Tumor count and tumor area data were analyzed
using a generalized linear model for a Poisson distribution on
a logarithmic link function [123], with allowance for over-
dispersion of the area data. Analysis was performed separately
for each a priori phase of tumor development: papilloma
emergence and regression (,weeks 11–19), transition from
papilloma to SCC (,weeks 20–25), and SCC progression (,week
26 onwards). Within a period, count (or area) data were averaged
and rounded to the nearest integer for each mouse. Rounded
averages were multivariately regressed on binary variables for
above vs. below median of each baseline anxiety variable plus an
unordered categorical variable for cage (to account for possible
clustering of responses within cages). Model assumptions were
verified per McCullagh and Nelder [123]. Estimation employed
least-squares means [124] to compare means of above-median vs.
below-median groups separately for each baseline anxiety variable.
Least squares means provide estimates of factor effects as if all
factor-level combinations have equal sample sizes, even if sample
sizes are unequal. This is especially important in experiments,
where typically no reason exists to weight factor-level combina-
tions differentially. Reported attained significance levels were one-
sided a priori; and statistical significance, p , 0.05 or p , 0.01, is
shown. Figures 2, 3, and 4, Tables 1 & 2, and corticosterone and
VEGF results: Data were grouped as above vs. below median for
each baseline behavior variable, for three separate two-group
comparisons. Outcomes were optimally Box-Cox transformed
[125] and compared between groups using a two-sample t-test
with Satterthwaite adjustment for unequal variances. The
corresponding effect size, d, a standardized measure of the
strength of the difference between two groups, is also indicated
with each p value. Application of Cohen’s standards for small,
medium and large effect sizes indicated that most effect sizes fell in
the ‘‘medium’’ to ‘‘large’’ range [126], even after adjustment for
the tendency of small samples to overestimate effect size [127,128].
To assess robustness of findings based on t-tests, we multivariately
regressed each outcome on time spent in the darkened area of the
arena and time spent in closed arms. Outcomes were Box-Cox
transformed and then outcomes and regressors were centered and
scaled [125], prior to analysis. Centering and scaling placed all
regression coefficients on a common scale to aid interpretation.
Estimated slopes farther from zero indicate stronger association.
For t-tests and regression analyses, reported attained significance
levels were one-sided a priori; and statistical significance, p , 0.05,
or trend, p , 0.09, is shown. Analyses were performed in SAS(R)
v.9.2 (SAS Institute, Cary, NC) and R v.2.9.1 (R Development
Core Team 2009).
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